Since the 1970s levodopa has been the cornerstone of PD management. Other dopaminergic agents, anticholinergics, MAO-B inhibitors, COMT inhibitors, and amantadine have also shown efficacy in the treatment of the disease. To date, we have a good supply of symptomatic medications that are effective for motor symptoms, but many non-motor problems in PD remain under recognized and under treated.
The development of disease-slowing therapies is perhaps the most pressing goal in PD drug development, but there is plenty of room for the development of better symptomatic therapies.
Here is the list of some agents that are currently being studied in PD:
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351(24):2509-2518.
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 suppl 4):1S-136.
Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010; 25:1774-1779.
Zesiewicz TA, Sullivan KL, Arnulf I, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of non-motor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924-931.